Search Results

Clene Inc. and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis and multiple sclerosis, announced that it will participate in the following investor conferences in May.

Clene Inc. today announced that management will present at the Emerging Growth Conference.

Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly-owned subsidiary Clene Nanomedicine Inc. today announced several key updates on its National Institutes of Health (NIH)-funded Accelerating Access to Critical Therapies Expanded Access Program (ACT-EAP) for CNM-Au8® compassionate use in ALS.

Clene Inc. and its wholly owned subsidiary Clene Nanomedicine, Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis and multiple sclerosis, announced its first quarter 2024 financial results and provided recent operating highlights for the CNM-Au8 clinical program for MS.

Clene Inc. and its wholly owned subsidiary Clene Nanomedicine Inc. presented new long-term CNM-Au8 treatment results for survival and neurofilament light levels from the HEALEY ALS Platform Trial open label extension at the European Network for the Cure of ALS meeting in Stockholm, Sweden.

Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc. today announced its full year 2023 financial results and provided recent operating highlights for the clinical programs in ALS and MS.

Clene Inc. today announced it presented new, preliminary data demonstrating the potential of CNM-Au8 as a treatment for Rett Syndrome.

Clene Inc. today announced that management will present at H.C. Wainwright’s 5th Annual Neuro Perspective Virtual Conference and host 1x1 investor meetings.